Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States.
It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib.
The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Zhengbin Yao |
Contact Details
Address: 18 Campus Boulevard, Suite 100 Newtown Square, Pennsylvania 19073 United States | |
| Phone | 628 277 4836 |
| Website | arrivent.com |
Stock Details
| Ticker Symbol | AVBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001868279 |
| ISIN Number | US04272N1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhengbin Yao | Chief Executive Officer |
| Winston Kung | Chief Financial Officer |
| Robin LaChapelle | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 8-K | Current Report |